Press release
Myelodysplastic Syndrome Drugs Market Analysis 2024 -2033: Forecasted Market Size, Top Segments, And Largest Region | Amgen Inc., Celgene Corporation, Otsuka Pharmaceutical Co. Ltd., Takeda Pharmaceutical Company Limited
Myelodysplastic Syndrome Drugs Market Characteristics
The Business Research Company offers in-depth market insights through Myelodysplastic Syndrome Drugs Global Market Report 2024, providing businesses with a competitive advantage by thoroughly analyzing the market structure, including estimates for numerous segments and sub-segments.
Market Size And Growth Forecast:
The myelodysplastic syndrome drugs market size has grown rapidly in recent years. It will grow from $2.07 billion in 2023 to $2.28 billion in 2024 at a compound annual growth rate (CAGR) of 10.2%. The growth in the historic period can be attributed to aging population, advancements in diagnostics, chemotherapy-related mds cases, increased cancer survivors, clinical research and drug development.
The myelodysplastic syndrome drugs market size is expected to see strong growth in the next few years. It will grow to $3.26 billion in 2028 at a compound annual growth rate (CAGR) of 9.3%. The growth in the forecast period can be attributed to growing geriatric population, advancements in targeted therapies, increased understanding of disease mechanisms, rising awareness and early diagnosis, expansion of oncology research. Major trends in the forecast period include erythropoiesis-stimulating agents optimization, combination therapies, increasing focus on iron chelation therapy, regulatory approvals and market access, patient-centric care models.
Get Free Sample Of This Report-
https://www.thebusinessresearchcompany.com/sample.aspx?id=10675&type=smp
Market Segmentation:
The myelodysplastic syndrome drugs market covered in this report is segmented -
1) By Therapeutic Class: Immunomodulatory Drugs, Hypomethylating Agents, Anti-anemics
2) By Type of Syndrome: Refractory Cytopenia With Multilineage Dysplasia, Refractory Anemia, Refractory Anemia With Excess Blasts, Refractory Anemia With Ringed Sideroblasts
3) By Route of Administration: Oral, Parenteral
4) By Applications: Original, Generics
5) By End-User: Hospitals, Clinics, Ambulatory Surgical Centers
Major Driver - Rising Mds Cases Fuel Growth In Myelodysplastic Syndrome Drug Market
The increase in the incidence of myelodysplastic syndrome is expected to propel the growth of the myelodysplastic syndrome drug market over the coming years. Myelodysplastic syndrome (MDS) is a group of disorders characterized by abnormal development and maturation of blood cells in the bone marrow. It is a type of blood cancer that primarily affects the production of healthy blood cells. Myelodysplastic syndrome drugs are used in treating myelodysplastic syndrome and involve medications to inhibit or modulate the immune system to lessen the requirement for red blood cell transfusions. For instance, in October 2022, according to the American Journal of Managed Care, a US-based magazine, The prevalence of myelodysplastic syndrome in the USA is estimated to be between 60,000 and 175,000 cases. Therefore, an increase in incidences of myelodysplastic syndrome is driving the growth of the myelodysplastic syndrome drug market.
Competitive Landscape:
Major companies operating in the myelodysplastic syndrome drugs market report are Amgen Inc., Celgene Corporation, Otsuka Pharmaceutical Co. Ltd., Takeda Pharmaceutical Company Limited, Cipla Limited, Dr. Reddy's Laboratories Ltd., Lupin Ltd., Onconova Therapeutics Inc., Sun Pharmaceutical Industries Limited, FibroGen Inc., Aprea Therapeutics, Bayer AG, Bristol Myers Squibb, Celator Pharmaceuticals, Crystal Genomics Inc., AbbVie Inc., Astex Pharmaceuticals Inc., Geron Co., Hikma Pharmaceuticals plc, Jazz Pharmaceuticals Inc., Mylan NV, Novartis AG, Sandoz Inc., Syros Pharmaceuticals, Teva Pharmaceutical Industries Ltd., Acceleron Pharma Inc., Agios Pharmaceuticals Inc., Incyte Corporation, Array Biopharma Inc., MEI Pharma Inc.
Get Access To The Full Market Report -
https://www.thebusinessresearchcompany.com/report/myelodysplastic-syndrome-drugs-global-market-report
Top Trend - Novartis Leads Research Innovation In Myelodysplastic Syndrome Drug Market
Research innovations are the key trend gaining popularity in the myelodysplastic syndrome drug market. Major companies operating in the myelodysplastic syndrome drug sector are focused on developing new technological and innovative solutions to strengthen their position in the market. For instance, in May 2021, Novartis, a Switzerland-based healthcare company, received FDA fast-track designation in myelodysplastic syndromes for Sabatolimab (MBG453). Sabatolimab is a first-in-class investigational immuno-myeloid therapy that binds to TIM-3, an innovative target articulated on numerous immune system cell types, leukemic cells, and blasts but not on normal stem cells that induce blood formation; it is being developed for HR-MDS and acute myeloid leukemia (AML). Fast-track designation expedites the development and approval of medications to treat serious illnesses and address unmet medical needs.
The Table Of Content For The Market Report Include:
1. Executive Summary
2. Myelodysplastic Syndrome Drugs Market Characteristics
3. Myelodysplastic Syndrome Drugs Market Trends And Strategies
4. Myelodysplastic Syndrome Drugs Market - Macro Economic Scenario
5. Myelodysplastic Syndrome Drugs Market Size And Growth
…..
27. Myelodysplastic Syndrome Drugs Market Competitor Landscape And Company Profiles
28. Key Mergers And Acquisitions
29. Future Outlook and Potential Analysis
30. Appendix
Contact us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 8897263534
Americas: +1 315 623 0293
Email: info@tbrc.info
Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
Facebook: https://www.facebook.com/TheBusinessResearchCompany
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Blog: https://blog.tbrc.info/
Healthcare Blog: https://healthcareresearchreports.com/
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
Latest Trending Press Releases: https://www.thebusinessresearchcompany.com/press-release.aspx
About The Business Research Company
The Business Research Company (www.thebusinessresearchcompany.com) is a market intelligence firm that pioneers in company, market, and consumer research. Located globally, TBRC's consultants specialize in various industries including manufacturing, healthcare, financial services, chemicals, and technology. The firm has offices located in the UK, the US, and India, along with a network of proficient researchers in 28 countries.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Myelodysplastic Syndrome Drugs Market Analysis 2024 -2033: Forecasted Market Size, Top Segments, And Largest Region | Amgen Inc., Celgene Corporation, Otsuka Pharmaceutical Co. Ltd., Takeda Pharmaceutical Company Limited here
News-ID: 3431035 • Views: …
More Releases from The Business research company
Emerging Trends to Reshape the Surgical Energy Instruments Market: Innovative Te …
Use code ONLINE30 to get 30% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts.
Surgical Energy Instruments Market Size Valuation Forecast: What Will the Market Be Worth by 2025?
In the past few years, the market size of surgical energy instruments has seen substantial growth. The market which is projected to be worth $4.68 billion in 2024, is expected to inflate to $5.2…
2025-2034 Spatial omics Market Evolution: Disruptions, Innovations, and Untapped …
Use code ONLINE30 to get 30% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts.
What Is the Expected CAGR for the Spatial omics Market Through 2025?
In recent years, the size of the spatial omics market has seen rapid expansion. The estimations show an increase to $0.33 billion in 2025 from $0.3 billion in 2024, marking a compound annual growth rate (CAGR) of…
Global Sigmoidoscope Market Projected to Grow at 6.1% CAGR, Reaching $3.38 Billi …
Use code ONLINE30 to get 30% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts.
What Will the Sigmoidoscope Industry Market Size Be by 2025?
In recent years, there has been a significant increase in the size of the sigmoidoscope market. The market is projected to expand from $2.53 billion in 2024 to $2.67 billion in 2025, demonstrating a compound annual growth rate (CAGR)…
2025-2034 Refurbished MRI Systems Market Roadmap: Insights for Competitive Advan …
Use code ONLINE30 to get 30% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts.
How Large Will the Refurbished MRI Systems Market Size By 2025?
The market size for refurbished MRI systems has experienced robust growth in the past few years. It is expected to rise from $0.77 billion in 2024 to $0.85 billion in 2025, showcasing a compound annual growth rate (CAGR)…
More Releases for Myelodysplastic
Myelodysplastic Syndrome Drugs Market Research and Treatment Advancements
On April 11, 2025, Exactitude Consultancy., Ltd. announces the release of the report "Global Myelodysplastic Syndrome Drugs Market 2025 by Manufacturers, Regions, Type and Application, Forecast to 2034". The report is a detailed and comprehensive analysis presented by region and country, type and application. As the market is constantly changing, the report explores the competition, supply and demand trends, as well as key factors that contribute to its changing demands…
Prominent Myelodysplastic Syndrome (MDS) Drugs Market Trend for 2025: Innovative …
What Are the Projected Growth and Market Size Trends for the Myelodysplastic Syndrome (MDS) Drugs Market?
The myelodysplastic syndrome (MDS) drugs market has expanded steadily in recent years. It is projected to increase from $3.47 billion in 2024 to $3.73 billion in 2025, reflecting a CAGR of 7.5%. The past growth can be attributed to the aging population, advancements in targeted therapies, ongoing clinical trials, and increased awareness.
The myelodysplastic syndrome (MDS)…
Myelodysplastic Syndrome (MDS) Treatment Market Insights, Forecast to 2031
"Myelodysplastic Syndrome (MDS) Treatment Market 2024,"
The objectives outlined in the report are multifaceted and aimed at offering a comprehensive understanding of the Myelodysplastic Syndrome (MDS) Treatment market dynamics. These objectives encompass a meticulous analysis and forecast of the market's dimensions, encompassing both its value and volume aspects. Additionally, the report seeks to discern and delineate the market shares held by major segments within the Myelodysplastic Syndrome (MDS) Treatment industry, providing stakeholders…
Myelodysplastic Syndrome Pipeline Outlook Report 2024 (Updated)
DelveInsight's, "Myelodysplastic Syndrome Pipeline Insight 2024" report provides comprehensive insights about 120+ companies and 150+ pipeline drugs in Myelodysplastic Syndrome pipeline landscape. It covers the Myelodysplastic Syndrome pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Myelodysplastic Syndrome pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Key Takeaways from the Myelodysplastic…
Myelodysplastic Syndrome Market Size, Epidemiology, Analysis & Trends 2023-2033
Market Overview:
The myelodysplastic syndrome market is expected to exhibit a CAGR of 6.51% during 2023-2033. The myelodysplastic syndrome market report offers a comprehensive analysis of the market in the United States, EU5 (including Germany, Spain, Italy, France, and the United Kingdom), and Japan. It covers aspects such as treatment methods, drugs available in the market, drugs in development, the market share of various therapies, and the market's performance in the…
Myelodysplastic Syndrome Market to see Huge Growth by 2029
Myelodysplastic Syndrome Market was valued at USD 2.8 billion in 2022 and is expected to grow at a CAGR of 10% between 2023 and 2029. Important changes in the business allow key players to attain larger profits. This Myelodysplastic Syndrome Market study report is the best way to make changes with the help of entire market condition and metrics provided here. These metrics also allow getting ahead in the industry.…
